These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 9083154

  • 1. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ, Kuzumaki N, Kawakami Y, Benedict WF.
    Cancer; 1997 Apr 01; 79(7):1329-37. PubMed ID: 9083154
    [Abstract] [Full Text] [Related]

  • 2. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S, Yasufuku K, Hiroshima K, Nakajima T, Yoshida S, Suzuki M, Sekine Y, Shibuya K, Iizasa T, Farouk A, Fujisawa T.
    Cancer; 2007 Jun 15; 109(12):2506-14. PubMed ID: 17487846
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis.
    Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF.
    Clin Cancer Res; 1996 Jul 15; 2(7):1169-76. PubMed ID: 9816284
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC.
    Clin Cancer Res; 2005 Jan 01; 11(1):232-41. PubMed ID: 15671551
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.
    Lung Cancer; 2004 Oct 01; 46(1):77-85. PubMed ID: 15364135
    [Abstract] [Full Text] [Related]

  • 11. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
    Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y.
    Cancer; 2003 Jan 15; 97(2):457-64. PubMed ID: 12518370
    [Abstract] [Full Text] [Related]

  • 12. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
    Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF.
    J Urol; 1997 Jul 15; 158(1):131-7. PubMed ID: 9186339
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ.
    Cancer Res; 1997 Feb 01; 57(3):433-9. PubMed ID: 9012470
    [Abstract] [Full Text] [Related]

  • 15. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer.
    Caputi M, Groeger AM, Esposito V, De Luca A, Masciullo V, Mancini A, Baldi F, Wolner E, Giordano A.
    Clin Cancer Res; 2002 Dec 01; 8(12):3850-6. PubMed ID: 12473599
    [Abstract] [Full Text] [Related]

  • 16. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma.
    Naka T, Toyota N, Kaneko T, Kaibara N.
    Anticancer Res; 1998 Dec 01; 18(1B):555-64. PubMed ID: 9568177
    [Abstract] [Full Text] [Related]

  • 17. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.
    Dosaka-Akita H, Hommura F, Mishina T, Ogura S, Shimizu M, Katoh H, Kawakami Y.
    Cancer Res; 2001 Mar 15; 61(6):2500-4. PubMed ID: 11289121
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K, Koizumi K, Haraguchi S, Hirata T, Mikami I, Fukushima M, Yamagishi S, Kawashima T, Okada D, Shimizu K, Kawamoto M.
    Ann Thorac Surg; 2005 Jan 15; 79(1):248-53. PubMed ID: 15620951
    [Abstract] [Full Text] [Related]

  • 19. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M.
    Oncogene; 1998 May 14; 16(19):2469-77. PubMed ID: 9627113
    [Abstract] [Full Text] [Related]

  • 20. p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
    Haque AK, Adegboyega P, Al-Salameh A, Vrazel DP, Zwischenberger J.
    Mod Pathol; 1999 Dec 14; 12(12):1158-66. PubMed ID: 10619270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.